Oncorus to Host Investor Day Featuring its IV-Administered Synthetic Viral RNA (vRNA) Immunotherapy Platform and Lead Synthet...
June 15 2021 - 7:57AM
Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company
focused on driving innovation to transform outcomes for cancer
patients, today announced that it will host an upcoming investor
day featuring its intravenous (IV)-administered Synthetic viral RNA
(vRNA) Immunotherapy Platform, and its recently nominated lead
Synthetic vRNA Immunotherapy product candidates, ONCR-021 and
ONCR-788. The virtual event will take place on June 21, 2021 from
1:00 – 2:30 p.m. ET.
Oncorus Synthetic vRNA Immunotherapies Day
Agenda
- Leena Ghandi, M.D., Ph.D., Director,
Center for Cancer Therapeutic Innovation at the Dana-Farber Cancer
Institute, will be a featured speaker at the event. Dr. Ghandi will
review current clinical practice and the potential for
IV-administered viral immunotherapies to address significant unmet
needs.
- Oncorus leadership will discuss the
company’s pioneering IV-administered approach, which involves
encapsulating the genomes of RNA viruses known to kill cancer cells
(i.e., oncolytic viruses, or OVs) within a lipid nanoparticle (or
LNP), creating a Synthetic vRNA immunotherapy. Oncorus’ novel
Synthetic vRNA approach holds the potential for repeat IV
administration and avoids the challenge of neutralizing antibodies
seen in previous approaches with IV-administered,
naturally-occurring OVs.
- Oncorus will review preclinical data
supporting the ONCR-021 and ONCR-788 candidate nominations and
discuss current clinical development plans for each program.
ONCR-021 encodes an optimized strain of Coxsackievirus A21 (CVA21),
and ONCR-788 encodes a modified version of the Seneca Valley Virus
(SVV).
- Finally, the company will also
provide an overview of its 88,000 square foot state-of-the-art
process development and Good Manufacturing Practice (GMP)
manufacturing facility in Andover, Mass., which it anticipates will
be operational for GMP manufacturing in the first half of
2023.
A live webcast of the event will be available to registered
attendees under the Investors and Media section of Oncorus’ website
at https://investors.oncorus.com/events-and-presentations. A
replay of the presentation will be archived on Oncorus’ site for 60
days following the event.
For more information or to RSVP, please contact Josh Rauch at
jrauch@soleburytrout.com.
Click here to read a white paper published by Oncorus’
leadership on it Synthetic vRNA Immunotherapy Platform and lead
candidates.
About Oncorus
At Oncorus, we are focused on driving innovation to deliver
next-generation viral immunotherapies to transform outcomes for
cancer patients. We are advancing a portfolio of intratumorally
(iTu) and intravenously (IV) administered viral immunotherapies for
multiple indications with significant unmet need based on our
oncolytic Herpes Simplex Virus (oHSV) and Synthetic viral RNA
(vRNA) Immunotherapy Platforms.
Designed to deliver next-generation viral immunotherapy impact,
our oHSV platform improves upon key characteristics of this
therapeutic class to enhance systemic activity. Our lead oHSV
program, ONCR-177, is designed to be directly administered into a
tumor, resulting in high local concentrations of the therapeutic
agent and its five encoded transgenes, as well as low systemic
exposure to the therapy, which could limit systemic toxicities. Our
pioneering Synthetic vRNA Immunotherapy Platform involves a highly
innovative, novel combination of RNA- and oncolytic virus-based
modalities to realize the potential of RNA medicines for cancer.
Our lead IV-administered Synthetic vRNA Immunotherapy clinical
candidates, ONCR-021 and ONCR-788, are both currently in
IND-enabling studies.
Please visit www.oncorus.com to learn more.
Cautionary Note Regarding Forward-Looking
Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, as amended, including, without limitation, implied and
express statements regarding the evolving immuno-oncology
landscape, the potential of Oncorus’ Synthetic vRNA Immunotherapy
Platform; preclinical and clinical development of ONCR-021 and
ONCR-788, including expectations regarding timelines for filing
INDs, as well as the product candidates’ therapeutic potential and
clinical benefits, mechanism of action and the utility; and
expectations regarding manufacturing capabilities including the
buildout timeline of Oncorus’ viral immunotherapy clinical
manufacturing facility. The words "may," “might,” "will," "could,"
"would," "should," "expect," "plan," "anticipate," "intend,"
"believe," “expect,” "estimate," “seek,” "predict," “future,”
"project," "potential," "continue," "target" and similar words or
expressions are intended to identify forward-looking statements,
although not all forward-looking statements contain these
identifying words. Any forward-looking statements in this press
release are based on management's current expectations and beliefs
and are subject to a number of risks, uncertainties and important
factors that may cause actual events or results to differ
materially from those expressed or implied by any forward-looking
statements contained in this press release, including, without
limitation, risks associated with: the impact of COVID-19 on
Oncorus’ operations and the timing and anticipated results of its
ongoing and planned clinical trials; the risk that the results of
preclinical studies and clinical trials may not be predictive of
future results in connection with future clinical trials; Oncorus’
ability to successfully demonstrate the safety and efficacy of
ONCR-021 and ONCR-788; Oncorus’ ability to secure adequate
quantities of viral immunotherapies manufactured in accordance with
regulatory requirements; the expansion of Oncorus’ in-house
manufacturing capabilities; the adequacy of Oncorus’ cash resources
and availability of financing on commercially reasonable terms; and
Oncorus’ ability to obtain, maintain and protect its intellectual
property. These and other risks and uncertainties are described in
greater detail in the section entitled "Risk Factors" in Oncorus’
Annual Report on Form 10-K for the year ended December 31,
2020, filed with the Securities and Exchange
Commission on March 10, 2021, as well as discussions of
potential risks, uncertainties, and other important factors in the
other filings that Oncorus makes with the Securities
and Exchange Commission from time to time. These documents are
available under the “SEC filings” page of the Investors section of
Oncorus’ website at http://investors.oncorus.com. Any
forward-looking statements represent Oncorus’ views only as of the
date of this press release and should not be relied upon as
representing its views as of any subsequent
date. Oncorus explicitly disclaims any obligation to
update any forward-looking statements, whether as a result of new
information, future events or otherwise. No representations or
warranties (expressed or implied) are made about the accuracy of
any such forward-looking statements.
Investor Contact: |
Media
Contact: |
Alan Lada |
Liz Melone |
Solebury Trout |
liz.melone@oncorus.com |
617-221-8006 |
|
alada@soleburytrout.com |
|
Oncorus (NASDAQ:ONCR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Oncorus (NASDAQ:ONCR)
Historical Stock Chart
From Jul 2023 to Jul 2024